Inhibrx Biosciences Inc (INBX) Actualités

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the...

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance PR Newswire SAN DIEGO, Jan. 13, 2025 SAN...

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results PR Newswire SAN DIEGO, Nov. 14, 2024 SAN...

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation PR Newswire SAN...

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities